Elevating precision medicine to the forefront of every cancer treatment journey
Our vision is a future in which each tumor’s unique genomic test result can be matched with a purpose-built precision medicine.
Together with our drug and diagnostic developer peers, we work to enable a personalized treatment plan for each individual patient with cancer.Our Focus
Genomic testing illuminates the path
Your tumor has a genomic fingerprint that may help your physician map the best path to overcoming it.
We advocate for every patient to get their tumor genomically tested. Only through testing can we give patients their best chance at improved outcomes.Learn More About Genomic Testing Patient-Doctor Discussion Guide
Blazing the trail to make genomic test results actionable
We develop drugs to inhibit the specific alterations that have been identified as drivers of cancer ⏤ no matter how rare.
Our lead drug candidate, seribantumab, inhibits tumor growth driven by NRG1 gene fusions. Seribantumab is being studied in CRESTONE, a Phase 2 trial for patients with solid tumors of any origin that test positive for an NRG1 fusion.Learn More About CRESTONE
Notes from the Trail
SHAWN LELAND | JANUARY 2021
The journey towards our first summit, NRG1 fusions, is well underway. We closed out 2020 with the release of the first preclinical data in support of the Phase 2 CRESTONE study at the EORTC-NCI-AACR conference in October, and a $65M Series B financing in November. We were thrilled to finally be able to publicly share this data showing 50-100% tumor regressions following treatment with seribantumab specifically in NRG1 fusion PDX models, and grateful to see this excitement reflected by our expanded Series B investor syndicate led by venBio and Cormorant Asset Management.Read the full letter